Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint BlockadeJun Zhou, F. Stephen Hodi, Michael P. Manos et al.|Cancer Immunology Research|2017Cited by 363
Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancerJoseph A. Sparano, Nancy E. Davidson, Molin Wang et al.|Cancer|2012Cited by 209
Race and Hormone Receptor–Positive Breast Cancer Outcomes in a Randomized Chemotherapy TrialJoseph A. Sparano, Nancy E. Davidson, Μolin Wang et al.|JNCI Journal of the National Cancer Institute|2012Cited by 109
Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast CancerBryan P. Schneider, Joseph A. Sparano, Fengmin Zhao et al.|Journal of Clinical Oncology|2012Cited by 99
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)A. Bapsi Chakravarthy, Al B. Benson, Fengmin Zhao et al.|The Oncologist|2019Cited by 21